Related Experiment Video
Updated: May 21, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Current standards in the treatment of chronic hepatitis C
Wolf Peter Hofmann1, Christoph Sarrazin, Stefan Zeuzem
1POLIKUM Berlin MVZ GmbH.
Insights
New hepatitis C treatments combining peginterferon and ribavirin with protease inhibitors like boceprevir or telaprevir significantly improve sustained virologic response (SVR) rates for genotype 1 infections. This triple therapy offers higher efficacy, especially for patients who previously did not respond well to treatment.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C virus (HCV) infection affects 400,000-500,000 people in Germany, with genotype 1 being the most prevalent.
- Standard peginterferon-alfa and ribavirin therapy achieves sustained virologic response (SVR) in 40-50% of genotype 1 patients and 70-80% of genotypes 2 and 3 patients.
- HCV protease inhibitors boceprevir and telaprevir were approved in Germany in 2011, offering new treatment options.
Purpose of the Study:
- To review the efficacy and application of new hepatitis C virus (HCV) treatments.
- To evaluate the impact of triple therapy regimens on sustained virologic response (SVR) rates.
- To discuss individualized treatment durations based on patient response and HCV genotype.
Main Methods:
- Selective literature review of studies on hepatitis C virus (HCV) treatment.
- Analysis of treatment outcomes for peginterferon-alfa, ribavirin, and protease inhibitor combinations.
- Evaluation of factors influencing sustained virologic response (SVR) rates, including genotype and viral load.
Main Results:
- Triple therapy with boceprevir or telaprevir, plus peginterferon and ribavirin, demonstrated higher SVR rates (66-75%) for genotype 1 compared to dual therapy (37-44%).
- Individualized treatment durations (24-72 weeks) are recommended based on HCV genotype, baseline viral load, and early viral decline.
- Higher SVR rates were observed in patients who failed prior dual therapy: 69-88% for relapsers, 52-59% for partial responders, and 33% for null responders.
- Triple combination therapy is associated with novel adverse events.
Conclusions:
- Individualized treatment durations for chronic hepatitis C are recommended with peginterferon and ribavirin.
- Triple therapy combining peginterferon, ribavirin, and either boceprevir or telaprevir significantly increases SVR rates.
- This enhanced efficacy applies to both previously untreated genotype 1 patients and those with prior antiviral treatment failure.
Background:
In Germany, 400 000 to 500 000 people are chronically infected with the hepatitis C virus (HCV), 70% to 80% of them with HCV genotype 1. Combined treatment with peginterferon-alfa and ribavirin leads to a sustained virologic response (SVR) in 40% to 50% of patients with genotype 1 and 70% to 80% of patients with genotypes 2 and 3. The HCV protease inhibitors boceprevir and telaprevir were approved for clinical use in Germany in 2011.
Methods:
Selective literature review.
Results:
Treatment with peginterferon and ribavirin is recommended for a variable length of time depending on the HCV genotype (24 to 72 weeks for genotype 1, 16 to 48 weeks for genotypes 2 and 3), the baseline HCV-RNA concentration (greater or less than 600 000 to 800 000 IU/mL), and the decline in HCV-RNA concentration after 4 and 12 weeks of treatment. Either boceprevir or telaprevir is given in addition to peginterferon and ribavirin. In the approval studies, these triple combinations were shown to yield higher SVR rates than dual treatment for genotype 1 (66% to 75% versus 37% to 44%). If there is a favorable early decline in HCV-RNA, the treatment can be shortened to 24 to 28 weeks in 44% to 65% of patients with genotype 1. The SVR rates in genotype 1 patients who failed previous dual therapy were 69% to 88% for prior relapsers, 52% to 59% for partial responders, and 33% for null responders. Triple combination therapy is associated with new adverse events.
Conclusion:
Individualized treatment durations are recommended for the treatment of chronic hepatitis C with peginterferon and ribavirin. Triple therapy in combination with either boceprevir or telaprevir leads to a higher rate of SVR both in previously untreated genotype 1 patients and in those who have failed prior antiviral treatment.\
More Related Videos
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
01:25Hepatitis
01:28Viral Hepatitis I: Introduction
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:23Cirrhosis I: Introduction
01:29Chronic Pancreatitis II: Collaborative Care
Assessment: